{"url_path":"/sec/txmd/8-k/2026-08-11/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-08-11","source_url":"https://www.sec.gov/Archives/edgar/data/25743/0001213900-26-087756-index.html","accession_number":"0001213900-26-087756","cik":"0000025743","ticker":"TXMD","issuer_name":"TherapeuticsMD, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/25743/0001213900-26-087756-index.html","primary_entity_key":"0000025743","primary_entity_name":"TherapeuticsMD, Inc."},"word_count":307,"has_tables":true,"body_markdown":"false\n0000025743\n\n0000025743\n\n2026-08-11\n2026-08-11\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n \n\n \n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**Washington, D.C. 20549**\n\n** **\n\n**FORM 8-K**\n\n** **\n\n**CURRENT REPORT**\n\n**PURSUANT TO SECTION 13 OR 15(d)**\n\n**OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n** **\n\n**DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED):\nAugust 11, 2026**\n\n** **\n\n**THERAPEUTICSMD, INC.**\n\n**(Exact Name of Registrant as Specified in its\nCharter)**\n\n \n\n**Nevada**\n \n**001-00100**\n \n**87-0233535**\n\n**(State or Other Jurisdiction\nof Incorporation)**\n \n**(Commission File Number)**\n \n**(IRS Employer\nIdentification No.)**\n\n** **\n\n**951 Yamato Road, Suite 220**\n\n**Boca Raton, FL 33431**\n\n**(Address of Principal Executive Office) (Zip\nCode)**\n\n** **\n\n**Registrant’s telephone number, including\narea code: (561) 961-1900**\n\n** **\n\n**Not Applicable**\n\n**(Former name or former address, if changed since\nlast report)**\n\n \n\nCheck the appropriate box below if the Form 8-K filing is intended\nto simultaneously satisfy the filing obligation of the registrant under any of the following provisions:\n\n \n\n☐\nWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n \n\n☐\nSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n \n\n☐\nPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n \n\n☐\nPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\n \n\nSecurities registered pursuant to Section 12(b) of the Act:\n\n \n\n**Title of Each Class**\n \n**Trading Symbol**\n \n**Name of Each Exchange on Which Registered**\n\nCommon Stock, par value $0.001 per share\n \nTXMD\n \nThe Nasdaq Stock Market LLC\n\n \n\nIndicate by check mark whether the registrant is an emerging growth\ncompany as defined in Rule 405 of the Securities Act of 1933 (§230-405) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2).\n\n \n\nEmerging growth company ☐\n\n \n\nIf an emerging growth company, indicate by check mark if the registrant\nhas elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant\nto Section 13(a) of the Exchange Act. ☐"}